Viewing Study NCT05391893


Ignite Creation Date: 2025-12-25 @ 1:11 AM
Ignite Modification Date: 2025-12-25 @ 11:22 PM
Study NCT ID: NCT05391893
Status: COMPLETED
Last Update Posted: 2024-12-27
First Post: 2021-09-23
Is NOT Gene Therapy: False
Has Adverse Events: True

Brief Title: Effect of Oral and Intravenous Diltiazem Protocol for Emergency Department Atrial Fibrillation
Sponsor: Corewell Health South
Organization:

Study Overview

Official Title: Emergency Department Atrial Fibrillation Oral Diltiazem Observation Protocol
Status: COMPLETED
Status Verified Date: 2023-10
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The primary objective of the study is to reduce hospital admission and decrease time to disposition through establishing an effective treatment protocol for AF and Atrial Flutter in the Emergency Department of Spectrum Health Lakeland. Secondary outcome is to measure if oral diltiazem is an effective HR controlling agent in AF RVR and Flutter.
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: False
Is an FDA AA801 Violation?: